LGVN — Longeveron LLC
NASDAQ · Healthcare · Biotechnology
$6.95
+$0.20 (+2.94%)
Longeveron LLC (LGVN) is a biotechnology company listed on NASDAQ. It is led by Stephen H. Willard Esq., based in Life Science & Technology Park, Miami, FL, United States, 33136, with about 38 employees. Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Latest reported LGVN revenue for 2025-09-30 was $137.0K. Net income was -$7.2M. Revenue was down 56.6% from 2025-06-30 to 2025-09-30. LGVN currently screens at market cap $26.5M.
Use this LGVN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LGVN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LGVN SEC filings page. Lician reads the product cache first so this HTML stays unique to Longeveron LLC even when a live quote feed is slow.
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
LGVN Key Statistics
Market Cap
$26.54M
Volume
1.10M
Previous Close
$0.84
Day Range
$0.65 – $0.73
P/B Ratio
1.67
EPS
-$2.62
Revenue
$2.39M
Net Income
-$15.97M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+237.4%
Profit Margin
-667.8%
Employees
38
LGVN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.39M | $709.00K | $1.22M | $1.31M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$15.97M | -$21.41M | -$18.84M | -$17.05M |
| EPS (Diluted) | -$2.62 | -$10.22 | -$0.90 | -$0.90 |
Total Assets
$25.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$19.23M
Operating Cash Flow
-$13.87M
Free Cash Flow
$0.00
Longeveron LLC Company Information
- Chief Executive Officer
- Stephen H. Willard Esq.
- Headquarters
- Life Science & Technology Park, Miami, FL, United States, 33136
- Website
- longeveron.com
- Phone
- 844 470 2550
- IPO / Founded
- 2021-02-12
- Sector
- Healthcare
- Industry
- Biotechnology